Vantage logo

A new reality for Immunocore

A private raise should crystallise what was already known to have been a valuation comedown for Immunocore and its troubled investor Neil Woodford.

Vantage logo

Where is the IPO class of 2014-15 now?

A golden age for biotech flotations yielded some spectacular blow-ups, but also saw several groups reward investors with premium-priced takeovers.